Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Primary cytomegalovirus (CMV) disease in high risk (D+/R‐) abdominal solid organ transplant recipients (aSOTRs) is well described, however little is known of primary CMV disease in low risk (D‐/R‐) patients.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>Observational study of adult aSOTRs between 1/1/2009‐9/1/2019 screened based on serostatus at transplant; D‐/R‐ and D+/R‐ patients were included. Primary objective: Describe epidemiology of primary CMV in D‐/R‐ aSOTRs. Secondary objective: compare infectious and transplant related outcomes of primary CMV disease in the first 90 days (early CMV) between D‐/R‐ and D+/R‐.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Of 782 D‐/R‐ aSOTRs in the study period, 13 developed CMV at any time after transplant to last follow‐up. Of 671 D+/R‐ patients, 186 developed CMV. Early CMV disease was significantly more common in the D‐/R‐ group (54% vs 15.6%, p=0.0005) despite populations being similar demographically, including allograft subtype. D‐/R‐ patients with early CMV disease had median viral load >100,000 IU/mL and 42.9% had end‐organ manifestations; 71.4% required hospital admission. Immunosuppressive therapy was adjusted in 100% of patients, there was an approximately 14.3% rate of antiviral resistance and 28.6% had concomitant opportunistic infection. These findings were similar to D+/R‐ patients. There was no difference in risk of rejection or all‐cause mortality associated with early CMV disease, however graft loss was significantly higher in D‐/R‐</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>D‐/R‐ aSOTRs infrequently develop CMV, however when it occurs, they present with disease manifestations similar to and graft outcomes inferior to D+/R‐ with CMV. Additionally, the majority of CMV disease in D‐/R‐ occurs in the first 90 days after transplant, suggesting possible donor subclinical infection or transfusion source. The complicated course in D‐/R‐ is likely due to low clinical suspicion. Awareness of disease severity and aggressive upfront management may promote positive outcomes.</p></section>

Bidirectional transfer of human cytomegalovirus strains in donor and recipient seropositive lung transplant patients

Protective Immunity Transferred by Infusion of Cytomegalovirus-Specific CD8(+) T Cells Within Donor Grafts: Its Associations with Cytomegalovirus Reactivation Following Unmanipulated Allogeneic Hematopoietic Stem Cell Transplantation.

Progress on the association between human gene polymorphisms and cytomegalovirus infection after transplantation

Relationship Between T-cell Receptor Beta Chain Sequences and Human Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients.

Dynamics and Evolution of Donor-derived Cytomegalovirus Infection in 3 Solid Organ Transplant Recipients With the Same Multiorgan Donor

Innate and adaptive effector immune drivers of cytomegalovirus disease in lung transplantation: a double-edged sword

Association of Cytomegalovirus Infection with Human Leukocyte Antigen Genotypes in Recipients after Allogeneic Liver Transplantation.

Reactivation of a transplant recipient's inherited human herpesvirus 6 and implications to the graft

Bidirectional transfer of Anelloviridae lineages between graft and host during lung transplantation

Early Immune Surveillance to Predict Cytomegalovirus Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation.

Impact and outcomes of primary cytomegalovirus disease in seronegative abdominal solid organ transplant recipients of cytomegalovirus unexposed donors (D‐/R‐)

Immune Control of Human Cytomegalovirus (HCMV) Infection in HCMV-Seropositive Solid Organ Transplant Recipients: The Predictive Role of Different Immunological Assays

Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation

Insights into cytomegalovirus-associated T cell receptors in recipients following allogeneic hematopoietic stem cell transplantation

MCMV Dissemination from Latently-Infected Allografts Following Transplantation into Pre-Tolerized Recipients

Recipient-donor KIR ligand matching prevents CMV reactivation post-haploidentical T cell-replete transplantation

Association between cytomegalovirus viremia and long-term outcomes in lung transplant recipients

Evolution of Cytomegalovirus-Responsive T Cell Clonality following Solid Organ Transplantation

Cytokine Dynamics and Herpesvirus Interactions in Pediatric Liver and Kidney Transplant Recipients: The Distinct Behavior of HCMV, HHV6, HHV7 and EBV

Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation

Longitudinal Detection of Twenty DNA and RNA Viruses in Allogeneic Hematopoietic Stem Cell Transplant Recipients Plasma